BioNTech's Strong Cancer Data Fails to Convince Markets as 36% Upside Beckons

BioNTech shares trade 26% below highs as COVID revenue slump overshadows promising cancer data. Analysts see 36% upside, but market awaits commercial proof.

BioNTech ended last week at €78.10 a share, a modest 2% gain that does little to close the chasm between its clinical momentum and its stock price. The Mainz-based biotech has been piling up encouraging oncology results — yet the market remains unimpressed, leaving the shares trading 26% below their 52-week high. Analysts see average upside of 36% to a target of around €106, but that optimism will require proof the company can turn scientific hits into commercial wins.

The latest wave of data came from the American Society of Clinical Oncology meeting in late May and early June. Pumitamig, tested in combination with chemotherapy for first-line lung cancer under the ROSETTA Lung-02 trial, achieved disease control in every patient. It was the third consecutive consistent dataset for the drug. Meanwhile, Gotistobart showed durable anti-tumor activity in heavily pre-treated ovarian cancer, with a manageable safety profile. These are the kind of readouts that normally lift a stock. BioNTech’s shares barely stirred.

That muted reaction reflects a more fundamental problem: the company is still perceived through the lens of its collapsing COVID-19 vaccine franchise. First-quarter revenue slid to €118.1 million, down from €182.8 million a year earlier, and the group posted a net loss of €531.9 million. Management reaffirmed full-year guidance of up to €2.3 billion, but the drag from the legacy business overshadows the pipeline progress. The stock has lost 14% over the past twelve months and trades comfortably below its 200-day moving average of €85.61. The short-term moving average also remains out of reach.

The technical picture underscores a waiting game. Shares are holding above the 2026 low of €68.35, but resistance at the 200-day line has kept rallies in check. Investors have shifted their focus from potential to pain: the transition from pandemic winner to oncology specialist is proving costly and slow. The planned departure of BioNTech’s co-founders adds leadership uncertainty that weighs at least as heavily as the clinical data.

Yet the bear case has a strong counter-argument in the breadth of the pipeline. BioNTech plans to launch six more phase 3 studies this year, bringing the total number of late-stage trials to 15. Seven important data updates are expected in the near term, spanning multiple tumor types. The oncology programme now encompasses more than 25 studies, a far cry from the single-product COVID vaccine story of two years ago. Management itself is putting money behind that conviction: a €1 billion share buyback programme is underway, a clear signal that executives consider the stock undervalued. The company also retains a sizeable cash buffer to fund the pivot.

The coming months will provide a clearer gauge of how quickly the financial transformation is proceeding. BioNTech is scheduled to give a business update on June 30, followed by second-quarter figures on August 4. For now, the stock remains a bet on future catalysts rather than current earnings. The analyst consensus of 36% upside looks compelling on paper, but the market has decided it needs to see late-stage trial results translate into regulatory filings and, eventually, commercial revenue. Those milestones are still some way off. A gradual revaluation is the most likely path — not a sudden jump back to former heights.